Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Managing Pediatric Atopic Dermatitis Nonresponse to Dupilumab and Emerging Therapies

Description

This discussion focused on how to manage pediatric atopic dermatitis that does not respond adequately to dupilumab, using an 8-year-old child as the main case. The speakers emphasized that before changing therapy, clinicians should reassess adherence, confirm correct use of moisturizers and topicals, and consider whether the disease is partially improving or not responding at all. They stressed the importance of looking for alternative or concurrent diagnoses, especially allergic or irritant contact dermatitis, and noted that patch testing can often still be performed while a patient is on dupilumab. Other possible contributors to persistent itch or rash include chronic urticaria and environmental triggers such as dust mites and pet dander. Treatment options discussed included increasing dupilumab dose off-label when appropriate, adding topical or systemic therapies, switching to broader immunosuppressants or JAK inhibitors, or pursuing patch testing before escalating treatment. The talk then reviewed the evolving landscape of pediatric eczema therapy: dupilumab remains the main FDA-approved biologic under age 12, but emerging options include IL-13 inhibitors, JAK inhibitors, and OX40 inhibitors, with the possibility that future care will be guided by clearer endotypes and biomarkers. Overall, the key message was that dupilumab nonresponse is common enough to require a structured evaluation, and management should be individualized based on phenotype, comorbid atopy, adherence, and suspected alternate diagnoses.

View more

Conclusions

In children with atopic dermatitis who respond only partially to dupilumab, the first step is to re-check adherence to moisturizers and topical therapy and to look for modifiable contributors such as contact dermatitis, urticaria, or environmental triggers.
Patch testing is presented as especially useful in dupilumab nonresponders, and it can generally be performed even while the patient remains on dupilumab.
A true nonresponse to dupilumab should prompt consideration of an alternate diagnosis or a switch to a broader systemic option rather than automatic dose escalation.
Patients who still benefit from dupilumab for other atopic comorbidities may be managed by continuing dupilumab and adding or adjusting therapy, whereas true nonresponders are better served by moving on to another treatment class.
Dupilumab is still the main FDA-approved systemic biologic option for children under 12 and is effective and safe for most patients, but a meaningful minority do not respond adequately.
Atopic dermatitis is heterogeneous, so treatment failure likely reflects different endotypes, concurrent diagnoses, adherence problems, or disease mechanisms beyond the IL-4/IL-13 axis.
Emerging IL-13 inhibitors may help some dupilumab nonresponders, but there is not yet enough evidence to predict who will benefit most.
JAK inhibitors appear more effective than dupilumab in head-to-head comparisons in older patients, and pediatric trials are underway to extend their use to younger children.
OX40-pathway inhibitors are promising because they may offer deeper, longer-lasting disease modification, but safety concerns remain and the evidence is still evolving.
The future of eczema care is likely to be more personalized, using biomarkers or other clinical endotyping to match patients with the therapy most likely to work for their specific disease pattern.

Drucker AM, et al. JAMA Dermatol. 2024.
Drucker AM et al., JAMA Dermatol. 2022.
Blauvelt A. et al., JAMA Dermatol. 2021.
Reich K. et al., Lancet. 2022.
Source: Guttman-Yassky, E, et al. Lancet. 2025.